Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809635 · ClinicalTrials.gov registry record
Study of BEST1 Vitelliform Macular Dystrophy
A clinical trial of Retinitis Pigmentosa and Best Vitelliform Macular Dystrophy, sponsored by Columbia University.
- Recruiting
- Registry status
- 52
- Enrollment target
- 3
- Study locations
NCT05809635: Recruiting study of Retinitis Pigmentosa and Best Vitelliform Macular Dystrophy, sponsored by Columbia University.
NCT05809635 is a study of Retinitis Pigmentosa and Best Vitelliform Macular Dystrophy that is actively recruiting participants, run by Columbia University. The registered enrollment target is 52 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05809635, a study of Retinitis Pigmentosa and Best Vitelliform Macular Dystrophy, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene. As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to: 1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s). 2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD. 3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment 4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.
Conditions Studied
Interventions
- OTHER Natural History Study
Study Locations (3)
Other
- Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts - Paris
- Eberhard Karls University Tubingen - Tübingen
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-05-31 |
What NCT05809635 shows while recruiting
NCT05809635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Natural History Study is the first listed.
NCT05809635 reports a single indexed study location in Other, New York.
Frequently Asked Questions
What is clinical trial NCT05809635 about?
NCT05809635 is a clinical study titled "Study of BEST1 Vitelliform Macular Dystrophy". The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene. As new treatments are develo...
What is the current status of trial NCT05809635?
This trial is currently recruiting. The enrollment target is 52 participants. The study started on 2021-03-30. Estimated completion is 2026-05-31.
What conditions does trial NCT05809635 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Best Vitelliform Macular Dystrophy.
What interventions are being tested in trial NCT05809635?
The interventions under investigation include: Natural History Study (OTHER).
Who is sponsoring clinical trial NCT05809635?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05809635 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05809635's enrollment target sits among peer trials
52 16th of 37 higher than 22 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI